219 related articles for article (PubMed ID: 32793196)
1. Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells.
Okuno D; Sugiura Y; Sakamoto N; Tagod MSO; Iwasaki M; Noda S; Tamura A; Senju H; Umeyama Y; Yamaguchi H; Suematsu M; Morita CT; Tanaka Y; Mukae H
Front Immunol; 2020; 11():1405. PubMed ID: 32793196
[TBL] [Abstract][Full Text] [Related]
2. Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug.
Tanaka Y; Murata-Hirai K; Iwasaki M; Matsumoto K; Hayashi K; Kumagai A; Nada MH; Wang H; Kobayashi H; Kamitakahara H; Okamura H; Sugie T; Minato N; Toi M; Morita CT
Cancer Sci; 2018 Mar; 109(3):587-599. PubMed ID: 29288540
[TBL] [Abstract][Full Text] [Related]
3. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.
Benzaïd I; Mönkkönen H; Stresing V; Bonnelye E; Green J; Mönkkönen J; Touraine JL; Clézardin P
Cancer Res; 2011 Jul; 71(13):4562-72. PubMed ID: 21646473
[TBL] [Abstract][Full Text] [Related]
4. Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid.
Idrees AS; Sugie T; Inoue C; Murata-Hirai K; Okamura H; Morita CT; Minato N; Toi M; Tanaka Y
Cancer Sci; 2013 May; 104(5):536-42. PubMed ID: 23387443
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Immunomodulatory Activity of Fluorine-Containing Bisphosphonates.
Mizuta S; Tagod MSO; Iwasaki M; Nakamura Y; Senju H; Mukae H; Morita CT; Tanaka Y
ChemMedChem; 2019 Feb; 14(4):462-468. PubMed ID: 30637982
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP.
Roelofs AJ; Jauhiainen M; Mönkkönen H; Rogers MJ; Mönkkönen J; Thompson K
Br J Haematol; 2009 Jan; 144(2):245-50. PubMed ID: 19016713
[TBL] [Abstract][Full Text] [Related]
7. Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma.
Umeyama Y; Taniguchi H; Gyotoku H; Senju H; Tomono H; Takemoto S; Yamaguchi H; Tagod MSO; Iwasaki M; Tanaka Y; Mukae H
Front Immunol; 2023; 14():1058838. PubMed ID: 37006249
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Mattarollo SR; Kenna T; Nieda M; Nicol AJ
Cancer Immunol Immunother; 2007 Aug; 56(8):1285-97. PubMed ID: 17265022
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced Vγ9Vδ2 T cell cytotoxicity in PC-3 prostate cancer cells.
Arkko S; Zlatev HP; Mönkkönen H; Räikkönen J; Benzaïd I; Clézardin P; Mönkkönen J; Määttä JA
Cancer Lett; 2015 Feb; 357(1):279-285. PubMed ID: 25444923
[TBL] [Abstract][Full Text] [Related]
10. Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation.
Nada MH; Wang H; Workalemahu G; Tanaka Y; Morita CT
J Immunother Cancer; 2017; 5():9. PubMed ID: 28239463
[TBL] [Abstract][Full Text] [Related]
11. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
Li Z; Tang J; Sun L; Ye Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710
[TBL] [Abstract][Full Text] [Related]
12. Expansion of human peripheral blood γδ T cells using zoledronate.
Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
[TBL] [Abstract][Full Text] [Related]
13. Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism.
Wang H; Sarikonda G; Puan KJ; Tanaka Y; Feng J; Giner JL; Cao R; Mönkkönen J; Oldfield E; Morita CT
J Immunol; 2011 Nov; 187(10):5099-113. PubMed ID: 22013129
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells.
Sugie T; Murata-Hirai K; Iwasaki M; Morita CT; Li W; Okamura H; Minato N; Toi M; Tanaka Y
Cancer Immunol Immunother; 2013 Apr; 62(4):677-87. PubMed ID: 23151944
[TBL] [Abstract][Full Text] [Related]
15. CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy.
Wang Y; Wang L; Seo N; Okumura S; Hayashi T; Akahori Y; Fujiwara H; Amaishi Y; Okamoto S; Mineno J; Tanaka Y; Kato T; Shiku H
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446055
[TBL] [Abstract][Full Text] [Related]
16. Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.
Tanaka Y; Iwasaki M; Murata-Hirai K; Matsumoto K; Hayashi K; Okamura H; Sugie T; Minato N; Morita CT; Toi M
Sci Rep; 2017 Jul; 7(1):5987. PubMed ID: 28729550
[TBL] [Abstract][Full Text] [Related]
17. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
18. Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells
Wang S; Li H; Ye C; Lin P; Li B; Zhang W; Sun L; Wang Z; Xue D; Teng W; Zhou X; Lin N; Ye Z
Front Immunol; 2018; 9():377. PubMed ID: 29535738
[TBL] [Abstract][Full Text] [Related]
19. Interplay of T-cell receptor and interleukin-2 signalling in Vγ2Vδ2 T-cell cytotoxicity.
Li H; David Pauza C
Immunology; 2011 Jan; 132(1):96-103. PubMed ID: 20738419
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.
Sato K; Kimura S; Segawa H; Yokota A; Matsumoto S; Kuroda J; Nogawa M; Yuasa T; Kiyono Y; Wada H; Maekawa T
Int J Cancer; 2005 Aug; 116(1):94-9. PubMed ID: 15756684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
